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INTRODUCTION
Soon after its discovery, hepatitis C virus (HCV) was identified as an independent risk factor for the development of hepatocellular carcinoma (HCC), especially in patients with cirrhosis, (1). Older age, male gender, and active hepatic necro-inflammation were also widely acknowledged as independent risk factors for HCC, regardless of the etiology of chronic liver disease (2,3).
Because no regimen has a proven antifibrotic effect, only drugs acting on the etiology of liver damage can stop the progression of liver fibrosis and, thus, indirectly reduce the risk of hepatic decompensation and of HCC (4) . Etiological treatment of patients with chronic HCV infection has progressed massively since the days of IFN-based regimens, in terms of effective viral clearance and of applicability. Until 2015, IFN-based therapy had limited indications; its effectiveness varied according to degree of fibrosis, stage of liver disease, viral genotype, and presence of co-morbidity (5, 6) . Despite these limitations, large cohorts of patients with compensated cirrhosis treated with IFN-based regimens and followed-up over the long term showed substantially reduced rates of disease decompensation, HCC incidence, and mortality, when a sustained virological response (SVR) was obtained (7) (8) (9) (10) . Unfortunately, the low SVR rate in these cohorts (<40%) and the limited applicability of IFN-based therapy for patients with advanced or decompensated liver disease reduced the relevance of these outcomes.
New regimens with direct-acting antiviral (DAA) agents have changed both the spectrum and the scope of treatment, all patients being amenable to viral eradication at any stage of liver disease. SVR rates to currently available combinations exceed 95% in real-life practice. Based on the results of trials (11, 12) , the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved DAA for all patients with chronic HCV liver disease, regardless of age, disease stage, and viral M A N U S C R I P T
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genotypes. Practice guidelines from AASLD (13) and EASL (14) recommend treating patients with compensated or decompensated cirrhosis with priority in order to reduce short-term complications.
While a reduction of deaths due to improved liver function is reported in a retrospective analysis of a large cohort of patients with advanced liver fibrosis treated with DAA (15) , data on the risk and modality of HCC occurrence in patients with cirrhosis are discordant (16) (17) (18) (19) (20) ; the first observational studies triggered a debate on the early incidence of HCC (21, 22) . This uncertainty could affect clinical practice; hence the safety of therapy in cirrhosis patients needs to be assessed in extensive, prospective, real-life cohort studies.
We report the outcome of a large prospective cohort of patients with HCV cirrhosis and no previous diagnosis of HCC, in order to assess the de novo occurrence of HCC, to identify risk factors associated with its occurrence, and to characterize the presentation of HCC according to HCV response to DAA. 
PATIENTS AND METHODS

RESIST-HCV (Rete
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STATISTICAL ANALYSIS
To evaluate the early occurrence of HCC, we included all patients who received a complete regimen of DAA treatment and were evaluated for SVR in the analysis. Data were analyzed using the R statistical computing environment (version 3.4) Data for continuous variables are presented as mean and SD or as median and range, and data for categorical variables are presented as frequency and percentage.
Differences between continuous data were analyzed by Student's t test. Chi-squared tests with Yates' continuity correction were used for dichotomous or categorical variables.
HCC occurrence rates were evaluated by means of Kaplan-Meier estimators, and differences among groups of patients were tested using log-rank (Mantel-Cox) tests.
Univariate and multivariate Cox regression analysis was used to identify baseline variables such as age, sex, diagnosis of diabetes, bilirubin, albumin, INR, platelet values, ChildPugh class, and SVR associated with the development of HCC.
Variables with a threshold value of <0.10 at univariate analysis were included in the multivariate model, and variables in the final model with P <0.05 were considered statistically significant. Results are expressed as adjusted hazard ratio (HR) with 95% confidence interval (CI).
RESULTS
Patient characteristics
From March 2015 to July 2016, 4,440 patients included in the RESIST-HCV database started DAA therapy; 2,877 of them had clinical criteria for diagnosis of cirrhosis. Of these patients, 273 (9.5%) were excluded from analysis because they had a previous diagnosis of HCC, had received a LT or were on the LT waiting list; 138 (4.8%) patients were not M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
11
included in the analysis because they did not have an SVR assessment; 217 (7.5%) were excluded by analysis because they had undergone ≥1 US after DAA (Supplementary Figure 1 ).
Analyses were performed on 2,249 consecutive adult patients with HCV cirrhosis who completed a full course of antiviral therapy with a DAA regimen (Supplementary Table 1 
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HCC incidence in HCV cirrhosis treated with DAA V. Calvaruso et al . Table 2 ). The analysis of HCC incidence according to Child-Pugh class and SVR status is shown in Figure 2 . In Child-Pugh class A, the cumulative rates of HCC at 1 yr were 2.1% in SVR patients and 6.6% in patients without SVR, while patients in Seventeen patients (0.76%) died during the observation period. Of these, 4 patients were M A N U S C R I P T
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in the group of 109 patients without SVR, and 13 patients were among the 2,140 patients who achieved SVR (P=0.008). Seven out of 78 patients (9%) who received the diagnosis of HCC (6 for liver failure and 1 for gastrointestinal bleeding) and 10 patients (0.5%) in the group of 2,171 patients without HCC diagnoses (1 for liver-related causes and 9 for nonliver-related causes) died during the observation period (P<0.001).
B. Risk factors associated with HCC
We analyzed the clinical characteristics of patients who developed HCC in comparison with patients without HCC ( Table 5 ).
Clinical features of HCC during observation
We assessed the interval between most recent US and initiation of DAA treatment, interval from start of DAA to diagnosis with HCC, tumor number and size of HCC nodules, presence of portal thrombosis and Barcelona Clinic Liver Cancer (BCLC) class in 78 patients diagnosed with HCC during the observation period (Supplementary Table 4 The remaining 71 patients (92%) received the diagnosis of HCC after the end of DAA. In
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
15
this group, the interval between US surveillance and start of DAA was 5.5 mo (range, 2-
19)
Mean interval from start of DAA exposure to HCC diagnosis was 9.8 mo (range, 2-22 mo); this measure was similar in patients with vs. without SVR (9.2 vs. 12.0 mo; P=0.11).
Regarding 
DISCUSSION
Widespread availability of DAA has enormously increased the number of HCV patients achieving SVR, including those with advanced or decompensated HCV cirrhosis.
Immediate evidence of the exceptional efficacy and tolerability of these regimens has not allowed for the design of RCTs with untreated control groups of patients, which are necessary to demonstrate the ultimate impact on clinical outcomes of liver disease. The lack of RCTs may be partially addressed by the assessment of large real-life cohorts.
However, such studies may be flawed by recruitment bias, retrospective analysis, and the inaccuracy of clinical goals scheduled at the start of treatment. In addition, the assumption that SVR may be considered a safe surrogate marker for clinical efficacy of DAA treatment at all stages of liver disease remains to be proven (24) .
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These uncertainties have fuelled a debate on two issues: a) the risk for and modality of HCC in cirrhotic patients treated with DAA (17-22); b) the effects of new antiviral drugs on the risk of developing liver disease events and liver-related mortality (15) .
Given the difficulty of designing and carrying out RCTs in patients treated with DAA, well-designed cohort studies are useful because they can be used to measure the would correctly identify >85% of patients with liver cirrhosis (24) . In about one-third of patients, diagnosis of cirrhosis was confirmed by the presence of EV at the time of EGS surveillance (25) . Although the diagnosis of cirrhosis was based on platelet count in only 11 patients, platelet count is a validated serum test for diagnosis of advanced fibrosis or cirrhosis (26) . Mean age of our patient cohort was considerably higher than that of previous cohorts treated with IFN-based therapy. Moreover, many patients had significant chronic co-morbidities.
The first strength of our study was that all patients had undergone US surveillance Approximately 40% of patients of our cohort were in the low-risk class and showed a predicted cumulative incidence of HCC per year <1%. On the other hand, 14.4% of SVR patients who had a more advanced disease profile with low albumin and PLT values.
Clinical evidence of portal hypertension predicted incidence per year of comorbid HCC (up to 7.3%).
These data indicate that in the heterogeneous population of cirrhotic patients that achieved SVR after DAA therapy, the risk of developing HCC should be assessed in relation to disease stage. Over 90% of the 887 patients in our cohort belonging to the lowest risk group (SVR with normal values of albumin and PLT) had a Child-Pugh score of 5, and only 1 out of 4 had esophageal varices. These patients had predicted cumulative M A N U S C R I P T
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incidence of HCC per year <1%, similar to that observed in patients treated with IFNbased therapy (27) . Most studies including only patients with Child-Pugh A class cirrhosis in patients aged <60 yr, reported a rate of HCC per 100 persons per year of 1% among patients achieving SVR (7, (28) (29) (30) (31) (32) (33) (34) . Patients included in risk groups 2 and 3 often have portal hypertension (EV rates >50%), advanced age (mean age >65 yr), and compromised liver function. For these reasons, they cannot be compared with patients included in cohorts treated with IFN-based therapy. As evidenced by studies on the natural history of cirrhosis (3, 35) , these patients have a greater risk of developing decompensation, HCC, and death due to liver conditions. Our data show that SVR patients in the intermediate risk group had a predicted cumulative incidence of HCC per year of 3.4%; this risk increased to 7.3% per year in the high-risk SVR group.
The grading of risk of developing HCC in relation to clinical stage of disease is only partially addressed by published studies (27) . In fact, previous authors have pointed out Our data conclusively show that the rate of de novo HCC was not higher than expected, in cirrhotic patients who achieved SVR after DAA, considering the stage of disease. We are convinced that in the coming year, hepatologists should carefully evaluate the stage of liver disease in patients treated with DAA to avoid selection bias and errors in evaluating the results of their studies.
Finally, we evaluated the HCC pattern. Recently, Romano et al (18) observed an unusual HCC pattern during and after DAA. While 61% of patients developed single small HCC nodules or 2-3 small HCC nodules, the remaining 39% were diagnosed with larger or aggressive, often infiltrative, tumors. This unusual pattern was more frequent during rather than after DAA treatment, in patients who did not achieve SVR. In our prospective study, we were able to evaluate the time of the last US and the time since the start of DAA and diagnosis of HCC, the number and the size of HCC nodules, the presence of portal thrombosis, and BCLC class. We therefore chose to consider the start of therapy as the starting point for observation. The 7 patients who received a diagnosis of HCC on DAA therapy had a mean interval from last US to the start of DAA of 4.8 mo. Therefore, the risk of failing to diagnose HCC at the start of therapy was particularly low. None of these patients had a multinodular or aggressive HCC pattern; all obtained SVR, and six received adequate therapy for HCC. Overall, patients with SVR were more likely to have single HCC or HCC <3 cm, compared with patients who did not achieve SVR. Finally, patients with SVR were more likely than patients without SVR to be classified as BCLC stage A.
Our data do not support the hypothesis that HCC that develops during DAA or early followup is more aggressive and more difficult to treat with available therapies (21, 22) . We do not agree with the hypothesis that profound immunological and molecular changes in the liver microenvironment following abrupt interruption of HCV replication may increase the M A N U S C R I P T
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risk of early HCC (41,42).
With the availability of a broad spectrum of DAA with high efficacy and tolerability, antiviral therapy should reach a rate of SVR close to 100%. Physicians will be able to eradicate HCV infection in all patients, but they must be able to inform patients about the risks for liver disease progression and complications. To give patients the correct information, the physicians must correctly grade disease stage before starting the therapy and suggest appropriate clinical follow-up (43).
We are aware that our study has some limitations. Therefore, longer follow-up is required to evaluate the risk for HCC, especially in patients with portal hypertension or co-morbidities such as diabetes or metabolic syndrome.
However, we believe that the observation period used for this study was adequate to demonstrate that the risk of developing HCC does not increase during early follow-up after HCV clearance.
One other limitation of this study is the potential heterogeneity among clinical centers participating in RESIST, in terms of competence in the diagnosis of HCC. We believe this limitation has been overcome through the application of radiological or histological guidelines for the diagnosis of HCC and through adequate monitoring.
Moreover, moderate heterogeneity is an intrinsic characteristic of all studies that include a high number of centers.
In conclusion, our prospective observational study confirms that the early benefit of 
